Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies

Table 2

Clinical data from studies with the main agents in clinical development in differentiated thyroid cancer.

Author (ref)	Pharmaceutical compound	𝑁	Response rate (%)	Stabilizations (%)	Progression-free survival (months)
Gupta-Abramson et al. [16]	Sorafenib	30	23	53	20
Kloss et al. [17]	Sorafenib	41	15	56	15
Ahmed et al. [18]	Sorafenib	34	20 (DTC)	48	12
Hoftijzer et al. [19]	Sorafenib	31	24	34	14
Capdevila et al. [20]	Sorafenib	34 (16 DTC)	19 (DTC)	50 (DTC)	13.5
Leboulleux et al. [21]	Vandetanib	145	8.3 versus 5.5	48 versus 37	11 versus 5.8
Cohen et al. [22]	Axitinib	60	30	38	18
Carr et al. [23]	Sunitinib	33	13 (DTC)	68 (DTC)	12.8
Cohen et al. [24]	Sunitinib	31	13	63	Not reported
Sherman et al. [25]	Lenvatinib	56	47 (DTC)	36 (DTC)	Not reported
Sherman et al. [26]	Motesanib	93	24	67	10
Bible et al. [27]	Pazopanib	37	49	46	11.8